Lineage Cell Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Lineage Cell Therapeutics de winst en omzet met respectievelijk 50.3% en 63.5% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 51.1% per jaar.

Belangrijke informatie

50.3%

Groei van de winst

51.1%

Groei van de winst per aandeel

Biotechs winstgroei	35.7%
Inkomstengroei	63.5%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	20 Aug 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DB:BT3 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	16	-34	-36	N/A	6
12/31/2025	8	-26	-30	N/A	7
12/31/2024	5	-28	-23	3	6
6/30/2024	6	-24	-22	-22	N/A
3/31/2024	8	-24	-24	-23	N/A
12/31/2023	9	-21	-29	-29	N/A
9/30/2023	9	-23	-31	-31	N/A
6/30/2023	11	-22	-32	-31	N/A
3/31/2023	12	-24	-33	-32	N/A
12/31/2022	15	-26	1	1	N/A
9/30/2022	14	-49	3	3	N/A
6/30/2022	13	-51	4	4	N/A
3/31/2022	9	-49	5	6	N/A
12/31/2021	4	-43	-24	-24	N/A
9/30/2021	4	-12	-24	-23	N/A
6/30/2021	2	-12	-24	-23	N/A
3/31/2021	2	-14	-22	-22	N/A
12/31/2020	2	-21	-20	-20	N/A
9/30/2020	3	-27	-20	-20	N/A
6/30/2020	3	-36	-22	-22	N/A
3/31/2020	3	-59	-28	-28	N/A
12/31/2019	4	-12	-32	-32	N/A
9/30/2019	3	-52	-34	-32	N/A
6/30/2019	3	31	-35	-32	N/A
3/31/2019	5	57	-32	-30	N/A
12/31/2018	5	-46	-34	-31	N/A
9/30/2018	5	-73	-33	-31	N/A
6/30/2018	6	-125	-33	-31	N/A
3/31/2018	4	-133	N/A	-33	N/A
12/31/2017	3	-20	N/A	-31	N/A
9/30/2017	4	47	N/A	-34	N/A
6/30/2017	3	64	N/A	-35	N/A
3/31/2017	4	100	N/A	-36	N/A
12/31/2016	6	34	N/A	-42	N/A
9/30/2016	6	25	N/A	-47	N/A
6/30/2016	7	-20	N/A	-50	N/A
3/31/2016	8	-54	N/A	-50	N/A
12/31/2015	7	-47	N/A	-45	N/A
9/30/2015	7	-45	N/A	-40	N/A
6/30/2015	6	-39	N/A	-37	N/A
3/31/2015	5	-39	N/A	-38	N/A
12/31/2014	5	-36	N/A	-39	N/A
9/30/2014	5	-45	N/A	-38	N/A
6/30/2014	5	-46	N/A	-36	N/A
3/31/2014	5	-44	N/A	-33	N/A
12/31/2013	4	-44	N/A	-30	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat BT3 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat BT3 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat BT3 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van BT3 ( 63.5% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.5% per jaar).

Hoge groei-inkomsten: De omzet van BT3 ( 63.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van BT3 naar verwachting over 3 jaar hoog zal zijn

Lineage Cell Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Recent updates

Insufficient new directors

Lineage Cell Therapeutics, Inc. Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance, at the 59th Annual Inner Ear Biology Workshop

Insufficient new directors

Lineage Cell Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Insufficient new directors

New minor risk - Profitability

First quarter 2024 earnings released: US$0.036 loss per share (vs US$0.026 loss in 1Q 2023)

Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit

Lineage Cell Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Insufficient new directors

Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors

No longer forecast to breakeven

Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

No longer forecast to breakeven

New minor risk - Profitability

No longer forecast to breakeven

Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting

Full year 2023 earnings released: US$0.12 loss per share (vs US$0.15 loss in FY 2022)

Lineage Cell Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Lineage Cell Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury

Independent Director recently bought €93k worth of stock

Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $14.000002 million.

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

Third quarter 2023 earnings released: US$0.041 loss per share (vs US$0.036 loss in 3Q 2022)

Lineage Cell Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Lineage Cell Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients Enrolled in A Phase 1/2A Clinical Study of RG6501

Lineage Cell Therapeutics, Inc. Announces the Results of Imaging Analyses Demonstrating Evidence of Rapid Improvement in Outside Retinal Structure from A Phase 1/2A Clinical Study of Rg6501

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven